Interview with Ralf Vayntrub, Founder & President, Invar
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you…
Invar
Last updated: 13.02.2014
Address: 2 Ploshchad Zhuravleva, bld.2, 107023 Moscow,Russia
Tel: +7 (495) 962-16-62
Web: http://www.invarpharma.com/
Company description
INVAR is the Russian, privately-owned, national pharmaceutical & biotechnology company forming a product portfolio on the basis of
long-term exclusive in-licensing or distribution agreements on marketing and sales for the Russian market with owners of innovative medicines.
Number of employees – 104
Activity areas: Gynecology and Obstetrics, Dermatology, Otolaryngology, Pediatrics
Areas of interest: Innovative original pharmaceuticals, preferably in the spheres of dermatology, gynecology, otorhinolaryngology (ENT) and pediatrics
Company geography: Representation in 15 key regions of the Russia
Products and services
Our dedicated team performs all key business processes:
• Regulatory & Clinical Affairs
• Marketing
• Sales Forces Organization
• Logistics & Supply Chain
• Commercial Operations
Products: Fluomizin, Gynoflor E (Medinova, Switzerland), Sinuforte (Hartington S.L., Spain), Epigen (Cheminova S.A., Spain), Skin Cap (Cheminova S.A., Spain)
Services: Registration, promotion and distribution of innovative pharmaceutical products within the territory of the Russia
Interviews
Related
Sputnik V / A Brief History of Russia’s Controversial Viral Vector COVID-19 Vaccine
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion…
Russia / Biocad Ramps up Sputnik V Manufacturing; Unlicensed Remdesivir Generics; Chinese Vaccine Rejection
The latest Russia Pharma News, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing,…
Russia / $7.4 bln for Healthcare Modernisation; Generics Push; Sputnik Vaccine Successes
The latest news from Russian pharma and healthcare including a big funding injection for primary care up to 2025,…
COVID-19 / Russia First Mover in Approving Vaccine Amid Widespread Criticism
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities,…
News Roundup / Russian Pharma: April 2020
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in…
Drug Shortages / An Increasing Concern in Russia
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening…
Russian bots targeted US and vaccines
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has…
Interview with Arman Voskertchyan, Managing Director, Johnson & Johnson…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this…
Interview with Eric Blondeau, Managing Director, Alliance Healthcare Russia
You took over this organization just three months ago, having previously headed businesses in industries as diverse…
Interview with Victor Dmitriev, General Director, Association of the Russian…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the…
Interview with Vladimir Shipkov, Executive Director, Association of…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of…
Interview with Andrew Somers, President & CEO, American Chamber of Commerce…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of…
